1
|
Matoq A, Shahanavaz S. Transcatheter Pulmonary Valve in Congenital Heart Disease. Interv Cardiol Clin 2024; 13:369-384. [PMID: 38839170 DOI: 10.1016/j.iccl.2024.03.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2024]
Abstract
Over the last 2 decades, experience with transcatheter pulmonary valve replacement (TPVR) has grown significantly and has become an effective and reliable way of treating pulmonary valve regurgitation, right ventricular outflow (RVOT) obstruction, and dysfunctional bioprosthetic valves and conduits. With the introduction of self-expanding valves and prestents, dilated native RVOT can be addressed with the transcatheter approach. In this article, the authors review the current practices, technical challenges, and outcomes of TPVR.
Collapse
Affiliation(s)
- Amr Matoq
- Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
| | - Shabana Shahanavaz
- Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| |
Collapse
|
2
|
Flores-Umanzor E, Alshehri B, Keshvara R, Wilson W, Osten M, Benson L, Abrahamyan L, Horlick E. Transcatheter-Based Interventions for Tetralogy of Fallot Across All Age Groups. JACC Cardiovasc Interv 2024; 17:1079-1090. [PMID: 38749587 DOI: 10.1016/j.jcin.2024.02.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/07/2023] [Revised: 01/31/2024] [Accepted: 02/13/2024] [Indexed: 05/26/2024]
Abstract
Tetralogy of Fallot (TOF) is the most common form of cyanotic congenital heart disease. Palliative procedures, either surgical or transcatheter, aim to improve oxygen saturation, affording definitive procedures at a later stage. Transcatheter interventions have been used before and after surgical palliative or definitive repair in children and adults. This review aims to provide an overview of the different catheter-based interventions for TOF across all age groups, with an emphasis on palliative interventions, such as patent arterial duct stenting, right ventricular outflow tract stenting, or balloon pulmonary valvuloplasty in infants and children and transcatheter pulmonary valve replacement in adults with repaired TOF, including the available options for a large, dilated native right ventricular outflow tract.
Collapse
Affiliation(s)
- Eduardo Flores-Umanzor
- Toronto Congenital Cardiac Centre for Adults, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada; Cardiology Department, Cardiovascular Institute, Hospital Clínic, University of Barcelona, Barcelona, Spain
| | - Bandar Alshehri
- Toronto Congenital Cardiac Centre for Adults, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada
| | - Rajesh Keshvara
- Toronto Congenital Cardiac Centre for Adults, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada
| | - William Wilson
- Royal Melbourne Hospital Cardiology, Parkville, Victoria, Australia
| | - Mark Osten
- Toronto Congenital Cardiac Centre for Adults, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada
| | - Lee Benson
- Toronto Congenital Cardiac Centre for Adults, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada; The Labatt Family Heart Centre, Division of Cardiology, The Hospital for Sick Children, The Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
| | - Lusine Abrahamyan
- Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Institute for Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada
| | - Eric Horlick
- Toronto Congenital Cardiac Centre for Adults, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.
| |
Collapse
|
3
|
Wong N, Shorofsky M, Lim DS. Catheter-based Interventions in Tetralogy of Fallot Across the Lifespan. CJC PEDIATRIC AND CONGENITAL HEART DISEASE 2023; 2:339-351. [PMID: 38161670 PMCID: PMC10755836 DOI: 10.1016/j.cjcpc.2023.09.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/14/2023] [Accepted: 09/07/2023] [Indexed: 01/03/2024]
Abstract
Surgical treatment of tetralogy of Fallot (TOF) involves surgical relief of right ventricular outflow tract (RVOT) obstruction and closure of ventricular septal defect. However, some patients may require staged palliation before surgical repair. This traditionally was achieved only with surgery but recently evolved to include catheter-based techniques. RVOT dysfunction occurs inevitably after the surgical repair of TOF and, depending on the surgical approach, manifests as either progressive stenosis, regurgitation, or a combination of both. This predisposes the individual to repeated RVOT interventions with the attendant risks of multiple open-heart surgeries. The advent of transcatheter pulmonary valve replacement has reduced the operative burden, and the expansion of transcatheter pulmonary valve replacement device platforms has widened the type and size of RVOT anatomies that can be treated. This review will discuss the transcatheter therapies available throughout the lifespan of the patient with TOF.
Collapse
Affiliation(s)
- Ningyan Wong
- Department of Cardiology, National Heart Centre Singapore, Singapore
- Division of Cardiovascular Medicine, Department of Medicine, University of Virginia, Charlottesville, Virginia, USA
| | - Michael Shorofsky
- Division of Cardiovascular Medicine, Department of Medicine, University of Virginia, Charlottesville, Virginia, USA
| | - D. Scott Lim
- Division of Cardiovascular Medicine, Department of Medicine, University of Virginia, Charlottesville, Virginia, USA
| |
Collapse
|
4
|
Patel ND, Levi DS, Cheatham JP, Qureshi SA, Shahanavaz S, Zahn EM. Transcatheter Pulmonary Valve Replacement: A Review of Current Valve Technologies. JOURNAL OF THE SOCIETY FOR CARDIOVASCULAR ANGIOGRAPHY & INTERVENTIONS 2022; 1:100452. [PMID: 39132347 PMCID: PMC11307711 DOI: 10.1016/j.jscai.2022.100452] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/08/2022] [Revised: 08/06/2022] [Accepted: 08/17/2022] [Indexed: 08/13/2024]
Abstract
Transcatheter pulmonary valve replacement was first performed by Dr Philip Bonhoeffer, who implanted a Medtronic Melody valve in a human in 2000. Over the past 2 decades, there have been many advances in transcatheter pulmonary valve technology. This includes the use of the SAPIEN transcatheter heart valve in the pulmonary position, modifications and refinements to valve implantation procedures, and development of self-expanding valves and prestents to treat large diameter native or patched right ventricular outflow tracts. This article reviews the current transcatheter pulmonary valve technologies with a focus on valve design, screening process, implant procedure, and clinical outcomes.
Collapse
Affiliation(s)
- Neil D. Patel
- Children’s Hospital Los Angeles, Los Angeles, California
| | - Daniel S. Levi
- Mattel Children's Hospital at The University of California, Los Angeles, Los Angeles, California
| | | | | | | | - Evan M. Zahn
- Cedars-Sinai Medical Center, Los Angeles, California
| |
Collapse
|
5
|
Tannous P, Nugent A. Transcatheter pulmonary valve replacement in native and nonconduit right ventricle outflow tracts. J Thorac Cardiovasc Surg 2021; 162:967-970. [DOI: 10.1016/j.jtcvs.2020.07.126] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/17/2020] [Revised: 07/17/2020] [Accepted: 07/27/2020] [Indexed: 01/24/2023]
|
6
|
Kim DW, Kamioka N, Babaliaros VC. Reply: Transcatheter Pulmonary Valve Replacement With 32-mm Balloon-Expandable Prosthesis: Another Strategy in Mildly Dilated RVOT. JACC Cardiovasc Interv 2021; 14:712-713. [PMID: 33736782 DOI: 10.1016/j.jcin.2021.01.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/25/2021] [Accepted: 01/26/2021] [Indexed: 10/21/2022]
|
7
|
Law MA, Chatterjee A. Transcatheter pulmonic valve implantation: Techniques, current roles, and future implications. World J Cardiol 2021; 13:117-129. [PMID: 34131475 PMCID: PMC8173335 DOI: 10.4330/wjc.v13.i5.117] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/26/2020] [Revised: 03/11/2021] [Accepted: 04/21/2021] [Indexed: 02/06/2023] Open
Abstract
Right ventricular outflow tract (RVOT) obstruction is present in a variety of congenital heart disease states including tetralogy of Fallot, pulmonary atresia/stenosis and other conotruncal abnormalities etc. After surgical repair, these patients develop RVOT residual abnormalities of pulmonic stenosis and/or insufficiency of their native outflow tract or right ventricle to pulmonary artery conduit. There are also sequelae of other surgeries like the Ross operation for aortic valve disease that lead to right ventricle to pulmonary artery conduit dysfunction. Surgical pulmonic valve replacement (SPVR) has been the mainstay for these patients and is considered standard of care. Transcatheter pulmonic valve implantation (TPVI) was first reported in 2000 and has made strides as a comparable alternative to SPVR, being approved in the United States in 2010. We provide a comprehensive review in this space–indications for TPVI, detailed procedural facets and up-to-date review of the literature regarding outcomes of TPVI. TPVI has been shown to have favorable medium-term outcomes free of re-interventions especially after the adoption of the practice of pre-stenting the RVOT. Procedural mortality and complications are uncommon. With more experience, recognition of risk of dreaded outcomes like coronary compression has improved. Also, conduit rupture is increasingly being managed with transcatheter tools. Questions over endocarditis risk still prevail in the TPVI population. Head-to-head comparisons to SPVR are still limited but available data suggests equivalence. We also discuss newer valve technologies that have limited data currently and may have more applicability for treatment of native dysfunctional RVOT substrates.
Collapse
Affiliation(s)
- Mark Aaron Law
- Department of Pediatric Cardiology, Division of Cardiology, University of Alabama at Birmingham, Birmingham, AL 35233, United States
| | - Arka Chatterjee
- Division of Cardiology, University of Arizona College of Medicine, Tuscon, AZ 85724, United States
| |
Collapse
|
8
|
Breatnach CR, McGuinness J, Ng LY, Franklin O, Redmond M, Nölke L, McMahon C, Oslizlok P, Walsh K, Kenny D. Procedural technique for hybrid pulmonary valve replacement in infants and small children. Eur J Cardiothorac Surg 2021; 59:823-830. [PMID: 33253364 DOI: 10.1093/ejcts/ezaa410] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/21/2020] [Revised: 10/05/2020] [Accepted: 10/18/2020] [Indexed: 11/12/2022] Open
Abstract
OBJECTIVES Hybrid approach to pulmonary valve replacement (PVR) in the paediatric population has been reported, although data in infants and small children are limited. Several strategies are now possible. The aim of this study is to review our hybrid PVR strategy in a complex patient cohort, outlining a variety of approaches employed in our centre. METHODS We performed a retrospective review of infants and small children who underwent hybrid PVR between May 2017 and April 2019 in a single tertiary cardiology centre. Medical records were reviewed to ascertain demographic, clinical and outcome data. RESULTS Ten patients with a median (interquartile range) age of 1.5 years (1.1-1.9) and weight of 8.8 kg (8-10.6) were managed with hybrid pulmonary valve insertion. Eight patients had perventricular approach (4 sternotomy and 4 subxiphoid) and 2 patients had surgically sutured valve. Six patients underwent cardiopulmonary bypass for associated lesions. Three had insertion of the valve into conduits and 7 were deployed into native right ventricular outflow tracts. The pulmonary valve was successfully inserted in all 10 patients with no mortality. Postprocedural complications included paravalvar leak in 2 patients, suspected endocarditis in 1 patient who developed early valve regurgitation and wound infection in 1 patient. CONCLUSIONS Several approaches to hybrid PVR may be employed in small children with a high success rate. Follow-up studies are required to evaluate longer term durability of these approaches compared to standard surgical replacement.
Collapse
Affiliation(s)
- Colm R Breatnach
- Department of Cardiology, Children's Health Ireland at Crumlin, Dublin, Ireland
| | - Jonathan McGuinness
- Department of Cardiothoracic Surgery, Children's Health Ireland at Crumlin, Dublin, Ireland
| | - Li Yen Ng
- Department of Cardiology, Children's Health Ireland at Crumlin, Dublin, Ireland
| | - Orla Franklin
- Department of Cardiology, Children's Health Ireland at Crumlin, Dublin, Ireland
| | - Mark Redmond
- Department of Cardiothoracic Surgery, Children's Health Ireland at Crumlin, Dublin, Ireland
| | - Lars Nölke
- Department of Cardiothoracic Surgery, Children's Health Ireland at Crumlin, Dublin, Ireland
| | - Colin McMahon
- Department of Cardiology, Children's Health Ireland at Crumlin, Dublin, Ireland
| | - Paul Oslizlok
- Department of Cardiology, Children's Health Ireland at Crumlin, Dublin, Ireland
| | - Kevin Walsh
- Department of Cardiology, Children's Health Ireland at Crumlin, Dublin, Ireland
| | - Damien Kenny
- Department of Cardiology, Children's Health Ireland at Crumlin, Dublin, Ireland
| |
Collapse
|
9
|
Matsuzaki Y, Wiet MG, Boe BA, Shinoka T. The Real Need for Regenerative Medicine in the Future of Congenital Heart Disease Treatment. Biomedicines 2021; 9:478. [PMID: 33925558 PMCID: PMC8145070 DOI: 10.3390/biomedicines9050478] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2021] [Revised: 04/19/2021] [Accepted: 04/24/2021] [Indexed: 11/23/2022] Open
Abstract
Bioabsorbable materials made from polymeric compounds have been used in many fields of regenerative medicine to promote tissue regeneration. These materials replace autologous tissue and, due to their growth potential, make excellent substitutes for cardiovascular applications in the treatment of congenital heart disease. However, there remains a sizable gap between their theoretical advantages and actual clinical application within pediatric cardiovascular surgery. This review will focus on four areas of regenerative medicine in which bioabsorbable materials have the potential to alleviate the burden where current treatment options have been unable to within the field of pediatric cardiovascular surgery. These four areas include tissue-engineered pulmonary valves, tissue-engineered patches, regenerative medicine options for treatment of pulmonary vein stenosis and tissue-engineered vascular grafts. We will discuss the research and development of biocompatible materials reported to date, the evaluation of materials in vitro, and the results of studies that have progressed to clinical trials.
Collapse
Affiliation(s)
- Yuichi Matsuzaki
- Center for Regenerative Medicine, The Abigail Wexner Research Institute at Nationwide Children’s Hospital, 700 Children’s Drive, T2294, Columbus, OH 43205, USA; (Y.M.); (M.G.W.)
| | - Matthew G. Wiet
- Center for Regenerative Medicine, The Abigail Wexner Research Institute at Nationwide Children’s Hospital, 700 Children’s Drive, T2294, Columbus, OH 43205, USA; (Y.M.); (M.G.W.)
| | - Brian A. Boe
- Department of Cardiology, The Heart Center, Nationwide Children’s Hospital, 700 Children’s Drive, T2294, Columbus, OH 43205, USA;
| | - Toshiharu Shinoka
- Center for Regenerative Medicine, The Abigail Wexner Research Institute at Nationwide Children’s Hospital, 700 Children’s Drive, T2294, Columbus, OH 43205, USA; (Y.M.); (M.G.W.)
- Department of Cardiothoracic Surgery, The Heart Center, Nationwide Children’s Hospital, 700 Children’s Drive, T2294, Columbus, OH 43205, USA
| |
Collapse
|
10
|
Horlick EM, Haas NA. Percutaneous Pulmonary Valve Replacement: What a Difference a Day Makes. J Am Coll Cardiol 2021; 76:2859-2861. [PMID: 33303075 DOI: 10.1016/j.jacc.2020.11.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/19/2020] [Accepted: 11/02/2020] [Indexed: 11/30/2022]
Affiliation(s)
- Eric M Horlick
- Division of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto Ontario.
| | - Nikolaus A Haas
- Department of Pediatric Cardiology and Intensive Care, Medical Hospital of the University of Munich, LMU Ludwig Maximilians University Munich, Munich, Germany
| |
Collapse
|
11
|
Fujimoto K, Kitano M, Sakaguchi H, Ohuchi H, Hoashi T, Ichikawa H, Shiraishi I, Kurosaki K. Morphological changes and number of candidates for transcatheter pulmonary valve implantation in conduits involving heterograft and artificial material. Heart Vessels 2021; 36:1384-1391. [PMID: 33649908 DOI: 10.1007/s00380-021-01808-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/13/2020] [Accepted: 02/12/2021] [Indexed: 11/28/2022]
Abstract
Heterograft and artificial materials have been used for extracardiac conduit implantation to create right ventricular (RV) to pulmonary artery (PA) continuity for biventricular repair in Japan because of the limited availability of homograft valves. However, few studies have examined morphological changes and number of candidates for transcatheter pulmonary valve implantation (TPVI) in which the conduit includes more than one type of material. Overall, 88 patients who underwent biventricular repair with an external conduit were included in this evaluation. Based on catheterization data and surgical records, we estimated morphological change in the RV outflow tract for each material and the number of candidates for Melody valve implantation based on premarket approval application criteria established by the U.S. Food and Drug Administration. There were 63 candidates for TPVI (72%, 63/88). Median anteroposterior and lateral diameter of the RV outflow tract was 20.4 mm (range 9.0-41.5) and 17.8 mm (range 9.5-34.9), respectively. Bovine pericardium tended to dilate by 11.2%. Polytetrafluoroethylene (ePTFE), homograft, and Dacron polyethylene terephthalate (PET) tended to become stenotic by 11.1%, 28.0%, and 13.4%, respectively. While ePTFE (27/33, 82%) and Dacron PET (2/2, 100%) were highly suitable for TPVI, bovine pericardium (32/48, 67%) was less suitable. In Japan, many patients with hemodynamic indications for TPVI following extracardiac conduit implantation to create RV to PA continuity may also meet the morphological indications.
Collapse
Affiliation(s)
- Kazuto Fujimoto
- Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan.
| | - Masataka Kitano
- Department of Pediatric Cardiology, Okinawa Prefectural Nanbu Medical Center and Children's Medical Center, Okinawa, Japan
| | - Heima Sakaguchi
- Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan
| | - Hideo Ohuchi
- Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan
| | - Takaya Hoashi
- Department of Pediatric Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan
| | - Hajime Ichikawa
- Department of Pediatric Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan
| | - Isao Shiraishi
- Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan
| | - Kenichi Kurosaki
- Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan
| |
Collapse
|
12
|
McElhinney DB, Sondergaard L, Armstrong AK, Bergersen L, Padera RF, Balzer DT, Lung TH, Berger F, Zahn EM, Gray RG, Hellenbrand WE, Kreutzer J, Eicken A, Jones TK, Ewert P. Endocarditis After Transcatheter Pulmonary Valve Replacement. J Am Coll Cardiol 2019; 72:2717-2728. [PMID: 30497557 DOI: 10.1016/j.jacc.2018.09.039] [Citation(s) in RCA: 86] [Impact Index Per Article: 17.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/25/2018] [Revised: 08/08/2018] [Accepted: 09/04/2018] [Indexed: 12/19/2022]
Abstract
BACKGROUND Endocarditis has emerged as one of the most concerning adverse outcomes in patients with congenital anomalies involving the right ventricular outflow tract (RVOT) and prosthetic valves. OBJECTIVES The aim of this study was to evaluate rates and potential risk factors for endocarditis after transcatheter pulmonary valve replacement in the prospective Melody valve trials. METHODS All patients in whom a transcatheter pulmonary valve (TPV) was implanted in the RVOT as part of 3 prospective multicenter studies comprised the analytic cohort. The diagnosis of endocarditis and involvement of the TPV were determined by the implanting investigator. RESULTS A total of 309 patients underwent transcatheter pulmonary valve replacement (TPVR) and were discharged with a valve in place. The median follow-up duration was 5.1 years, and total observation until study exit was 1,660.3 patient-years. Endocarditis was diagnosed in 46 patients (median 3.1 years after TPVR), and a total of 35 patients were reported to have TPV-related endocarditis (34 at the initial diagnosis, 1 with a second episode). The annualized incidence rate of endocarditis was 3.1% per patient-year and of TPV-related endocarditis was 2.4% per patient-year. At 5 years post-TPVR, freedom from a diagnosis of endocarditis was 89% and freedom from TPV-related endocarditis was 92%. By multivariable analysis, age ≤12 years at implant (hazard ratio: 2.3; 95% confidence interval: 1.2 to 4.4; p = 0.011) and immediate post-implant peak gradient ≥15 mm Hg (2.7; 95% confidence interval: 1.4 to 4.9; p = 0.002) were associated with development of endocarditis and with development of TPV-related endocarditis (age ≤12 years: 2.8; 95% confidence interval: 1.3 to 5.7; p = 0.006; gradient ≥15 mm Hg: 2.6; 95% confidence interval: 1.3 to 5.2; p = 0.008). CONCLUSIONS Endocarditis is an important adverse outcome following TVPR in children and adults with post-operative congenital heart disease involving the RVOT. Ongoing efforts to understand, prevent, and optimize management of this complication are paramount in making the best use of TPV therapy. (Melody Transcatheter Pulmonary Valve [TPV] Study: Post Approval Study of the Original Investigational Device Exemption [IDE] Cohort; NCT00740870; Melody Transcatheter Pulmonary Valve Post-Approval Study; NCT01186692; and Melody Transcatheter Pulmonary Valve [TPV] Post-Market Surveillance Study; NCT00688571).
Collapse
Affiliation(s)
| | - Lars Sondergaard
- The Heart Center, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | | | | | - Robert F Padera
- Brigham and Women's Hospital, Children's Hospital Boston and Harvard Medical School, Boston, Massachusetts
| | | | | | | | - Evan M Zahn
- Cedars-Sinai Heart Institute, Los Angeles, California
| | | | | | | | | | | | | |
Collapse
|
13
|
Balzer D. Pulmonary Valve Replacement for Tetralogy of Fallot. Methodist Debakey Cardiovasc J 2019; 15:122-132. [PMID: 31384375 DOI: 10.14797/mdcj-15-2-122] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Right ventricular outflow tract (RVOT) dysfunction is common following surgical repair of tetralogy of Fallot and other forms of complex congenital heart disease. This results in pulmonary stenosis or regurgitation and may ultimately lead to RV failure and dysrhythmias. Transcatheter valve technologies are now available to treat certain patients with RVOT dysfunction. Current devices include the Medtronic Melody valve and the Edwards Lifesciences SAPIEN XT. Although these valves are approved for use in dysfunctional circumferential RVOT conduits, they are increasingly being used off label for nonconduit outflow tracts. Procedural complications include but are not limited to conduit rupture and coronary compression. Longer-term complications include stent fracture and endocarditis. Outcomes with these valves have demonstrated durable relief of stenosis and regurgitation. The Medtronic Harmony valve and the Alterra Prestent from Edwards Lifesciences are investigational devices that are intended to treat the patulous RVOT that is too large to accommodate currently available valves. This review will focus on current indications to treat RVOT dysfunction, existing transcatheter valve technologies, and investigational devices undergoing clinical trials. Hopefully, within the not-too-distant future, transcatheter pulmonary valve implantation will be feasible in the vast majority of patients with RVOT dysfunction following surgical repair of congenital heart disease.
Collapse
Affiliation(s)
- David Balzer
- ST. LOUIS CHILDREN'S HOSPITAL, ST. LOUIS, MISSOURI
| |
Collapse
|
14
|
Qureshi AM, Bansal N, McElhinney DB, Boudjemline Y, Forbes TJ, Maschietto N, Shahanavaz S, Cheatham JP, Krasuski R, Lamers L, Chessa M, Morray BH, Goldstein BH, Noel CV, Wang Y, Gillespie MJ. Branch Pulmonary Artery Valve Implantation Reduces Pulmonary Regurgitation and Improves Right Ventricular Size/Function in Patients With Large Right Ventricular Outflow Tracts. JACC Cardiovasc Interv 2019; 11:541-550. [PMID: 29566799 DOI: 10.1016/j.jcin.2018.01.278] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/19/2017] [Revised: 01/15/2018] [Accepted: 01/23/2018] [Indexed: 02/07/2023]
Abstract
OBJECTIVES The authors sought to assess the intermediate-term effects of percutaneous placed valves in the branch pulmonary artery (PA) position. BACKGROUND Most patients with large right ventricular outflow tracts (RVOTs) are excluded from available percutaneous pulmonary valve options. In some of these patients, percutaneous branch PA valve implantation may be feasible. The longer-term effects of valves in the branch PA position is unknown. METHODS Retrospective data were collected on patients with significant pulmonary regurgitation who had a percutaneous branch PA valve attempted. RESULTS Percutaneous branch PA valve implantation was attempted in 34 patients (18 bilateral and 16 unilateral). One-half of the patients were in New York Heart Association (NHYA) functional class III or IV pre-implantation. There were 2 failed attempts and 6 procedural complications. At follow-up, only 1 patient had more than mild valvar regurgitation. The right ventricular end-diastolic volume index decreased from 147 (range: 103 to 478) ml/m2 to 101 (range: 76 to 429) ml/m2, p < 0.01 (n = 16), and the right ventricular end-systolic volume index decreased from 88.5 (range: 41 to 387) ml/m2 to 55.5 (range: 40.2 to 347) ml/m2, p < 0.01 (n = 13). There were 5 late deaths. At a median follow-up of 2 years, all other patients were in NYHA functional class I or II. CONCLUSIONS Percutaneous branch PA valve implantation results in a reduction in right ventricular volume with clinical benefit in the intermediate term. Until percutaneous valve technology for large RVOTs is refined and more widely available, branch PA valve implantation remains an option for select patients.
Collapse
Affiliation(s)
- Athar M Qureshi
- The Lillie Frank Abercrombie Section of Cardiology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas; Center of Pediatric and Congenital Heart Disease, Cleveland Clinic Children's and Pediatric Institute, The Cleveland Clinic, Cleveland, Ohio; Department of Cardiovascular Medicine, Heart and Vascular Institute, The Cleveland Clinic, Cleveland, Ohio.
| | - Neha Bansal
- Division of Pediatric Cardiology, Children's Hospital of Michigan, Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan
| | - Doff B McElhinney
- Departments of Pediatrics and Cardiothoracic Surgery, Lucile Packard Children's Hospital Heart Center, Stanford University School of Medicine, Palo Alto, California
| | - Younes Boudjemline
- Department of Paediatric Cardiology, Centre de Référence Malformations Cardiaques Congénitales Complexes-M3C, Necker Hospital for Sick Children, Assistance Publique des Hôpitaux de Paris, Paris, France
| | - Tom J Forbes
- Division of Pediatric Cardiology, Children's Hospital of Michigan, Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan
| | - Nicola Maschietto
- Pediatric Cardiology Unit, Department of Women's and Children's Health, University of Padua, Padova, Italy
| | - Shabana Shahanavaz
- Division of Pediatric Cardiology, Washington University School of Medicine, St. Louis, Missouri
| | | | - Richard Krasuski
- Department of Cardiovascular Medicine, Heart and Vascular Institute, The Cleveland Clinic, Cleveland, Ohio; Division of Cardiology, Duke University Medical Center, Durham, North Carolina
| | - Luke Lamers
- American Family Children's Hospital, Madison, Wisconsin
| | - Massimo Chessa
- Pediatric and Adult Congenital Heart Center, IRCCS-Policlinico San Donato-University Hospital, Milan, Italy
| | - Brian H Morray
- Division of Cardiology, Seattle Children's Hospital, University of Washington, Seattle, Washington
| | - Bryan H Goldstein
- The Heart Institute, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine; Cincinnati, Ohio
| | - Cory V Noel
- The Lillie Frank Abercrombie Section of Cardiology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas
| | - Yunfei Wang
- The Lillie Frank Abercrombie Section of Cardiology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas
| | - Matthew J Gillespie
- The Cardiac Center at the Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
| |
Collapse
|
15
|
Rogers T, Ratnayaka K. CMR in Transcatheter Valve Interventions: State of the Art and Future Directions. CURRENT CARDIOVASCULAR IMAGING REPORTS 2019. [DOI: 10.1007/s12410-019-9486-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
16
|
Sinha S, Aboulhosn J, Levi DS. Transcatheter Pulmonary Valve Replacement in Congenital Heart Disease. Interv Cardiol Clin 2019; 8:59-71. [PMID: 30449422 DOI: 10.1016/j.iccl.2018.08.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Patients with dysfunctional right ventricular outflow tracks comprise a large portion of patients with severe congenital heart disease. Transcatheter pulmonary valve replacement in patients with dysfunctional right ventricular outflow tracks is feasible, safe, and efficacious. This article reviews current transcatheter valve replacement technology for dysfunctional right ventricular outflow tract and pulmonary valvular disease and its applications to patients with congenital heart disease. Discussed are the approach and preprocedural planning, current options, and applications of transcatheter pulmonary valve therapy. Also considered are future directions in this field as the technologies begin to develop further.
Collapse
Affiliation(s)
- Sanjay Sinha
- Department of Pediatrics, Division of Cardiology, UCLA Mattel Children's Hospital, Los Angeles, CA, USA.
| | - Jamil Aboulhosn
- Department of Pediatrics, Division of Cardiology, UCLA Mattel Children's Hospital, Los Angeles, CA, USA; Department of Medicine, Division of Cardiology, Ahmanson/UCLA Adult Congenital Heart Disease Center, Ronald Reagan UCLA Medical Center, 100 Medical Plaza, Suite 630E, Los Angeles, CA 90024, USA
| | - Daniel S Levi
- Division of Cardiology, UCLA Mattel Children's Hospital, University of California Los Angeles Medical School, 200 UCLA Medical Plaza #330, Los Angeles, CA 90095, USA
| |
Collapse
|
17
|
Abstract
Congenital heart disease (CHD) is the most common birth defect, occurring in approximately 0.8% to 1.0% of neonates. Advances in medical and surgical therapies for children with CHD have resulted in a growing population of patients reaching adulthood, with survival rates exceeding 85%. Many of these patients, especially if managed inappropriately, face the prospect of future complications including heart failure and premature death. For adults with uncorrected or previously palliated CHD, percutaneous therapies have become the primary treatment for many forms of CHD. In this article, we discuss the role of transcatheter interventions in the treatment of adults with CHD.
Collapse
Affiliation(s)
- Hussam S Suradi
- Interventional Cardiology, Structural Heart & Valve Center, St. Mary Medical Center, 1500 South Lake Park Avenue, Suite 100, Hobart, IN 46342, USA; Department of Cardiology, Community Hospital, Munster, IN 46321, USA; Rush Center for Structural Heart Disease, Rush University Medical Center, Chicago, IL 60612, USA.
| | - Ziyad M Hijazi
- Sidra Cardiac Program, Department of Pediatrics, Sidra Medical & Research Center, Weill Cornell Medicine, PO Box 26999, Doha, Qatar
| |
Collapse
|
18
|
Sinha S, Aboulhosn J, Asnes J, Bocks M, Zahn E, Goldstein BH, Zampi J, Hellenbrand W, Salem M, Levi D. Initial results from the off‐label use of the SAPIEN S3 valve for percutaneous transcatheter pulmonary valve replacement: A multi‐institutional experience. Catheter Cardiovasc Interv 2018; 93:455-463. [DOI: 10.1002/ccd.27973] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/13/2018] [Revised: 10/15/2018] [Accepted: 10/19/2018] [Indexed: 11/09/2022]
Affiliation(s)
- Sanjay Sinha
- Department of Pediatrics, Division of CardiologyUCLA Mattel Children's Hospital Los Angeles California
| | - Jamil Aboulhosn
- Department of Pediatrics, Division of CardiologyUCLA Mattel Children's Hospital Los Angeles California
- Department of MedicineAhmanson Adult Congenital Heart Disease Center, David Geffen School of Medicine at UCLA Los Angeles California
| | - Jeremy Asnes
- Department of Pediatrics, Division of Cardiology, Yale Medical Center New Haven Connecticut
| | - Martin Bocks
- Department of Pediatrics, Division of Pediatric CardiologyUH Rainbow Babies and Children's Hospital Cleveland Ohio
| | - Evan Zahn
- Guerin Family Congenital Heart ProgramThe Heart Institute and Department of Pediatrics Cedars‐Sinai Medical Center Los Angeles California
| | - Bryan H. Goldstein
- Department of Pediatrics, Division of CardiologyCincinnati Children's Hospital Cincinnati Ohio
| | - Jeffrey Zampi
- Department of Pediatrics, Division of CardiologyUniversity of Michigan Ann Arbor Michigan
| | - William Hellenbrand
- Department of Pediatrics, Division of Cardiology, Yale Medical Center New Haven Connecticut
| | - Morris Salem
- Department of Pediatrics, Division of CardiologyKaiser Permanente Los Angeles California
| | - Daniel Levi
- Department of Pediatrics, Division of CardiologyUCLA Mattel Children's Hospital Los Angeles California
- Department of MedicineAhmanson Adult Congenital Heart Disease Center, David Geffen School of Medicine at UCLA Los Angeles California
| |
Collapse
|
19
|
Boudjemline Y. Percutaneous pulmonary valve implantation: what have we learned over the years? EUROINTERVENTION 2018; 13:AA60-AA67. [PMID: 28942387 DOI: 10.4244/eij-d-17-00501] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Percutaneous pulmonary valve implantation has been widely accepted as an alternative to surgery in selected patients with right ventricular outflow tract (RVOT) dysfunction. This totally new field of our specialty pushed centres to rethink overall strategies on how to treat RVOT dysfunction. In this review, we will focus on challenges related to patient selection, and discuss innovative procedural techniques developed over the years to enlarge the number of candidates for the technique.
Collapse
Affiliation(s)
- Younes Boudjemline
- Cardiac Catheterization Laboratories, Sidra Cardiac Program, Sidra Medical & Research Center, Doha, Qatar
| |
Collapse
|
20
|
Ghobrial J, Aboulhosn J. Transcatheter valve replacement in congenital heart disease: the present and the future. Heart 2018; 104:1629-1636. [PMID: 29490935 DOI: 10.1136/heartjnl-2016-310898] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Affiliation(s)
- Joanna Ghobrial
- Ahmanson/UCLA Adult Congenital Heart Disease Center, UCLA Medical Center, Los Angeles, California, USA.,Cleveland Clinic Adult Congenital Heart Disease Center, Cleveland Clinic Foundation, Cleveland, OH, USA
| | - Jamil Aboulhosn
- Ahmanson/UCLA Adult Congenital Heart Disease Center, UCLA Medical Center, Los Angeles, California, USA
| |
Collapse
|
21
|
Landmark lecture on interventional cardiology: interventional cardiac catheterisation for CHD: the past, present, and the future. Cardiol Young 2017; 27:1974-1985. [PMID: 29286271 DOI: 10.1017/s1047951117002141] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
CHD affects millions of patients worldwide. Interventional therapies for CHD goes back to the mid-1960s when Bill Rashkind performed balloon atrial septostomy on a cyanotic baby with transposition of the great vessels. This was followed by development of balloon catheters to perform balloon valvuloplasties and angioplasties in the early to late 1980s. Although King and Mills performed the first transcatheter closure of secundum atrial septal defect in the mid-1970s, this procedure was better realised in the mid-1990s. More intracardiac defect closures were performed in the late 1990s and early 2000. This brings us to the current era of percutaneous valve implantation as developed by Bonhoeffer. In this paper, we will discuss the past, present, and future of interventional cardiac catheterisation for CHD patients.
Collapse
|
22
|
Abstract
PURPOSE OF REVIEW Our review is intended to provide readers with an overview of disease processes involving the pulmonic valve, highlighting recent outcome studies and guideline-based recommendations; with focus on the two most common interventions for treating pulmonic valve disease, balloon pulmonary valvuloplasty and pulmonic valve replacement. RECENT FINDINGS The main long-term sequelae of balloon pulmonary valvuloplasty, the gold standard treatment for pulmonic stenosis, remain pulmonic regurgitation and valvular restenosis. The balloon:annulus ratio is a major contributor to both, with high ratios resulting in greater degrees of regurgitation, and small ratios increasing risk for restenosis. Recent studies suggest that a ratio of approximately 1.2 may provide the most optimal results. Pulmonic valve replacement is currently the procedure of choice for patients with severe pulmonic regurgitation and hemodynamic sequelae or symptoms, yet it remains uncertain how it impacts long-term survival. Transcatheter pulmonic valve replacement is a rapidly evolving field and recent outcome studies suggest short and mid-term results at least equivalent to surgery. The Melody valve® was FDA approved for failing pulmonary surgical conduits in 2010 and for failing bioprosthetic surgical pulmonic valves in 2017 and has been extensively studied, whereas the Sapien XT valve®, offering larger diameters, was approved for failing pulmonary conduits in 2016 and has been less extensively studied. Patients with pulmonic valve disease deserve lifelong surveillance for complications. Transcatheter pulmonic valve replacement is a novel and attractive therapeutic option, but is currently only FDA approved for patients with failing pulmonary conduits or dysfunctional surgical bioprosthetic valves. New advances will undoubtedly increase the utilization of this rapidly expanding technology.
Collapse
|
23
|
McRae ME, Coleman B, Atz TW, Kelechi TJ. Patient outcomes after transcatheter and surgical pulmonary valve replacement for pulmonary regurgitation in patients with repaired tetralogy of Fallot: A quasi-meta-analysis. Eur J Cardiovasc Nurs 2017; 16:539-553. [PMID: 28756698 DOI: 10.1177/1474515117696384] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
BACKGROUND Individuals with repaired tetralogy of Fallot develop pulmonary regurgitation that may cause symptoms (dyspnea, chest pain, palpitations, fatigue, presyncope, and syncope), impair functional capacity, and may affect health-related quality of life. Surgical pulmonary valve replacement is the gold standard of treatment although transcatheter pulmonary valve replacement is becoming more common. Patients want to know whether less invasive options are as good. AIMS This analysis aimed to examine the differences in surgical versus transcatheter pulmonary valve replacement effects in terms of physiological/biological variables, symptoms, functional status and health-related quality of life. METHODS This quasi-meta-analysis included 85 surgical and 47 transcatheter pulmonary valve replacement studies published between 1995-2016. RESULTS In terms of physiological/biological variables, both surgical and transcatheter pulmonary valve replacement improved pulmonary regurgitation and systolic and diastolic right ventricular volume indices but not heart function. In the left heart, only surgical pulmonary valve replacement improved heart function. Only transcatheter pulmonary valve replacement improved left ventricular end-diastolic indices and neither improved endsystolic indices. Only surgery has been demonstrated to decrease QRS duration but there is little evidence of arrhythmia reduction. Symptom change is poorly documented. Functional class improves but exercise capacity generally does not. Some aspects of health-related quality of life improve with surgery and in one small transcatheter pulmonary valve replacement study. CONCLUSION Transcatheter and surgical pulmonary valve replacement compare favorably for heart remodeling. Exercise capacity does not change with either technique. Health-related quality of life improves after surgical pulmonary valve replacement. There are numerous gaps in documentation of changes in arrhythmias and symptoms.
Collapse
Affiliation(s)
- Marion E McRae
- 1 Medical University of South Carolina, USA.,2 Guerin Family Congenital Heart Program, Cedars-Sinai Medical Center, USA.,3 David Geffen School of Medicine, University of California at Los Angeles
| | - Bernice Coleman
- 4 Nursing Research Department, Cedars-Sinai Medical Center, USA
| | - Teresa W Atz
- 5 College of Medicine, Medical University of South Carolina, USA
| | | |
Collapse
|
24
|
Rapetto F, Kenny D, Turner M, Parry A, Stoica S, Uzun O, Caputo M. Hybrid Surgery Options for Complex Clinical Scenarios in Adult Patients with Congenital Heart Disease: Three Case Reports. Front Surg 2017; 4:7. [PMID: 28232910 PMCID: PMC5298988 DOI: 10.3389/fsurg.2017.00007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2016] [Accepted: 01/24/2017] [Indexed: 12/03/2022] Open
Abstract
The strategy for the management of adult patients with congenital heart disease (CHD) often represents a challenge for cardiac surgeons and cardiologists due to complex anatomy, wide range of clinical presentations, and a high-risk profile. However, hybrid approach may represent an attractive solution. We report three cases of adult patients previously operated for CHD and recently treated with a hybrid approach in our institution. Case 1: a 76-year-old woman with permanent atrial fibrillation, lung disease, chronic kidney disease, microcytic anemia, and type II diabetes mellitus, previously operated for atrial septal defect closure and pulmonary valvotomy, presented with severe pulmonary regurgitation and advanced right ventricular failure. In order to minimize the surgical risk, a hybrid approach was used: an extensive right ventricular outflow tract (RVOT) plication was followed by implantation of an Edwards Sapien XT prosthesis in the RVOT through the right ventricular apex, without cardiopulmonary bypass. Case 2: a 64-year-old man with previous atrial septum excision and pericardial baffle for partial anomalous pulmonary venous drainage with intact interatrial septum, presented with worsening dyspnea, right ventricular failure, and pulmonary hypertension caused by baffle stenosis. His comorbidities included coronary artery disease, atrial flutter, and previous left pneumonectomy. After performing a redo longitudinal median sternotomy, a 20-mm stent was implanted in the baffle with access through the superior vena cava. Case 3: a 50-year-old man, with previous atrioventricular septal defect repair, followed by mitral valve replacement with a mechanical prosthesis, subsequently developed a paravalvular leak (PVL) with severe mitral regurgitation and severe left ventricular dysfunction. He underwent a transapical PVL device closure with two Amplatzer Vascular Plugs. In our opinion, hybrid surgery is a promising therapeutic modality that increases the available treatment options for this patient population. A multidisciplinary and patient-tailored approach is crucial in these complex clinical scenarios.
Collapse
Affiliation(s)
- Filippo Rapetto
- Department of Cardiac Surgery, Bristol Heart Institute, University of Bristol, Bristol, UK; Department of Cardiac Surgery, Bristol Royal Hospital for Children, University of Bristol, Bristol, UK
| | - Damien Kenny
- Department of Paediatric Cardiology, Rush University Medical Center , Chicago, IL , USA
| | - Mark Turner
- Department of Cardiology, Bristol Heart Institute, University of Bristol , Bristol , UK
| | - Andrew Parry
- Department of Cardiac Surgery, Bristol Heart Institute, University of Bristol, Bristol, UK; Department of Cardiac Surgery, Bristol Royal Hospital for Children, University of Bristol, Bristol, UK
| | - Serban Stoica
- Department of Cardiac Surgery, Bristol Heart Institute, University of Bristol, Bristol, UK; Department of Cardiac Surgery, Bristol Royal Hospital for Children, University of Bristol, Bristol, UK
| | - Orhan Uzun
- Department of Paediatric Cardiology, University Hospital of Wales , Cardiff , UK
| | - Massimo Caputo
- Department of Cardiac Surgery, Bristol Heart Institute, University of Bristol, Bristol, UK; Department of Cardiac Surgery, Bristol Royal Hospital for Children, University of Bristol, Bristol, UK
| |
Collapse
|
25
|
Affiliation(s)
- Doff B. McElhinney
- From the Lucille Packard Children’s Hospital, Stanford University School of Medicine, Palo Alto, CA
| |
Collapse
|
26
|
Kubicki R, Stiller B, Grohmann J. Dysfunctional pulmonary artery conduit and co-existing large pseudoaneurysm: well-suited for a percutaneous approach with the Melody valve? SPRINGERPLUS 2016; 5:1575. [PMID: 27652148 PMCID: PMC5025400 DOI: 10.1186/s40064-016-3273-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/02/2016] [Accepted: 09/08/2016] [Indexed: 11/18/2022]
Abstract
Pseudoaneurysm formation is a rare but potentially life-threatening complication after surgical repair of congenital heart disease. We present a boy with truncus arteriosus communis 14 years after homograft placement in pulmonary position. On follow-up, he presented progressive chronic homograft degeneration. Moreover, a large pseudoaneurysm in the right ventricular outflow tract was surprisingly depicted. We opted for a two-stage interventional approach.
Collapse
|
27
|
Moustafa GA, Kolokythas A, Charitakis K, Avgerinos DV. Therapeutic Utilities of Pediatric Cardiac Catheterization. Curr Cardiol Rev 2016; 12:258-269. [PMID: 26926291 PMCID: PMC5304250 DOI: 10.2174/1573403x12666160301121253] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/05/2015] [Revised: 12/17/2015] [Accepted: 12/27/2015] [Indexed: 11/29/2022] Open
Abstract
In an era when less invasive techniques are favored, therapeutic cardiac catheterization constantly evolves and widens its spectrum of usage in the pediatric population. The advent of sophisticated devices and well-designed equipment has made the management of many congenital cardiac lesions more efficient and safer, while providing more comfort to the patient. Nowadays, a large variety of heart diseases are managed with transcatheter techniques, such as patent foramen ovale, atrial and ventricular septal defects, valve stenosis, patent ductus arteriosus, aortic coarctation, pulmonary artery and vein stenosis and arteriovenous malformations. Moreover, hybrid procedures and catheter ablation have opened new paths in the treatment of complex cardiac lesions and arrhythmias, respectively. In this article, the main therapeutic utilities of cardiac catheterization in children are discussed.
Collapse
Affiliation(s)
| | | | | | - Dimitrios V Avgerinos
- Department of Cardiothoracic Surgery, Athens Medical Center & Center for Percutaneous Valves and Aortic Diseases, 5-7 Distomou Street, 15125, Marousi, Attica, Greece.
| |
Collapse
|
28
|
Levi DS, Sinha S, Salem MM, Aboulhosn JA. Transcatheter native pulmonary valve and tricuspid valve replacement with the sapien XT: Initial experience and development of a new delivery platform. Catheter Cardiovasc Interv 2016; 88:434-43. [DOI: 10.1002/ccd.26398] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/01/2015] [Revised: 12/15/2015] [Accepted: 12/21/2015] [Indexed: 11/11/2022]
Affiliation(s)
- Daniel S. Levi
- Department of Pediatrics, Division of Cardiology; UCLA Mattel Children's Hospital; Los Angeles California
| | - Sanjay Sinha
- Department of Pediatrics, Division of Cardiology; UCLA Mattel Children's Hospital; Los Angeles California
| | - Morris M. Salem
- Department of Pediatrics, Division of Cardiology; Kaiser Permanente; Los Angeles California
| | - Jamil A. Aboulhosn
- Department of Medicine; Ahmanson Adult Congenital Heart Disease Center, David Geffen School of Medicine at UCLA; Los Angeles California
| |
Collapse
|
29
|
McElhinney DB, Cabalka AK, Aboulhosn JA, Eicken A, Boudjemline Y, Schubert S, Himbert D, Asnes JD, Salizzoni S, Bocks ML, Cheatham JP, Momenah TS, Kim DW, Schranz D, Meadows J, Thomson JD, Goldstein BH, Crittendon I, Fagan TE, Webb JG, Horlick E, Delaney JW, Jones TK, Shahanavaz S, Moretti C, Hainstock MR, Kenny DP, Berger F, Rihal CS, Dvir D. Transcatheter Tricuspid Valve-in-Valve Implantation for the Treatment of Dysfunctional Surgical Bioprosthetic Valves. Circulation 2016; 133:1582-93. [DOI: 10.1161/circulationaha.115.019353] [Citation(s) in RCA: 140] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/04/2015] [Accepted: 02/19/2016] [Indexed: 11/16/2022]
Abstract
Background—
Off-label use of transcatheter aortic and pulmonary valve prostheses for tricuspid valve-in-valve implantation (TVIV) within dysfunctional surgical tricuspid valve (TV) bioprostheses has been described in small reports.
Methods and Results—
An international, multicenter registry was developed to collect data on TVIV cases. Patient-related factors, procedural details and outcomes, and follow-up data were analyzed. Valve-in-ring or heterotopic TV implantation procedures were not included. Data were collected on 156 patients with bioprosthetic TV dysfunction who underwent catheterization with planned TVIV. The median age was 40 years, and 71% of patients were in New York Heart Association class III or IV. Among 152 patients in whom TVIV was attempted with a Melody (n=94) or Sapien (n=58) valve, implantation was successful in 150, with few serious complications. After TVIV, both the TV inflow gradient and tricuspid regurgitation grade improved significantly. During follow-up (median, 13.3 months), 22 patients died, 5 within 30 days; all 22 patients were in New York Heart Association class III or IV, and 9 were hospitalized before TVIV. There were 10 TV reinterventions, and 3 other patients had significant recurrent TV dysfunction. At follow-up, 77% of patients were in New York Heart Association class I or II (
P
<0.001 versus before TVIV). Outcomes did not differ according to surgical valve size or TVIV valve type.
Conclusions—
TVIV with commercially available transcatheter prostheses is technically and clinically successful in patients of various ages across a wide range of valve size. Although preimplantation clinical status was associated with outcome, many patients in New York Heart Association class III or IV at baseline improved. TVIV should be considered a viable option for treatment of failing TV bioprostheses.
Collapse
Affiliation(s)
- Doff B. McElhinney
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - Allison K. Cabalka
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - Jamil A. Aboulhosn
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - Andreas Eicken
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - Younes Boudjemline
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - Stephan Schubert
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - Dominique Himbert
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - Jeremy D. Asnes
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - Stefano Salizzoni
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - Martin L. Bocks
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - John P. Cheatham
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - Tarek S. Momenah
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - Dennis W. Kim
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - Dietmar Schranz
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - Jeffery Meadows
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - John D.R. Thomson
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - Bryan H. Goldstein
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - Ivory Crittendon
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - Thomas E. Fagan
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - John G. Webb
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - Eric Horlick
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - Jeffrey W. Delaney
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - Thomas K. Jones
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - Shabana Shahanavaz
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - Carolina Moretti
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - Michael R. Hainstock
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - Damien P. Kenny
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - Felix Berger
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - Charanjit S. Rihal
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| | - Danny Dvir
- From Stanford University, Palo Alto, CA (D.B.M.); Mayo Clinic, Rochester, MN (A.K.C., C.J.R.); University of California Los Angeles (J.A.A.); German Heart Centre, Munich, Germany (A.E.); Necker Enfants Malades Hospital, Paris, France (Y.B.); Deutsches Herzzentrum Berlin, Germany (S. Schubert, B.G.); Bichat Hospital, Paris, France (D.H.); Yale University, New Haven, CT (J.D.A.); Città della Salute e della Scienza, Molinette, Torino, Italy (S. Salizzoni); University of Michigan, Ann Arbor (M.L.B.)
| |
Collapse
|
30
|
Abu Saleh WK, Lin CH, Breinholt JP, Ramlawi B. Hybrid Approach to Pulmonary Valve Replacement with Melody Prosthesis Following Pulmonary Banding. J Card Surg 2016; 31:174-6. [DOI: 10.1111/jocs.12695] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Affiliation(s)
| | - Chun H. Lin
- Houston Methodist DeBakey Heart and Vascular Center; Houston Texas
| | - John P. Breinholt
- Department of Pediatrics; University of Texas Health Sciences Center; Houston Texas
| | - Basel Ramlawi
- Houston Methodist DeBakey Heart and Vascular Center; Houston Texas
| |
Collapse
|
31
|
The Utility of Intracardiac Echocardiography Following Melody™ Transcatheter Pulmonary Valve Implantation. Pediatr Cardiol 2015; 36:1754-60. [PMID: 26169526 DOI: 10.1007/s00246-015-1230-5] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/03/2015] [Accepted: 07/03/2015] [Indexed: 02/07/2023]
Abstract
The aim of this study was to determine the utility of intracardiac echocardiography (ICE) in assessing Melody™ transcatheter pulmonary valve (TPV) function immediately following valve implantation. ICE is used increasingly in percutaneous cardiac interventions. At our center, ICE is routinely utilized to evaluate valve function following Melody TPV implantation, but the utility of this practice remains unclear. A retrospective review of all Melody valves placed in the right ventricular outflow tract from April 2010 to September 2013 was performed. The clinical utility of ICE was described, along with the relationship between ICE data and traditional hemodynamic/angiographic data. ICE was performed in 54 cases and provided excellent Melody TPV visualization with no complications. ICE did not change clinical management but did provide supplemental information in two cases. In one case, angiography showed severe catheter-related Melody insufficiency. Subsequent ICE confirmed no insufficiency and prevented the need for additional angiography. In the second case, ICE allowed characterization of the mechanism of a residual gradient. ICE did not detect any clinically significant paravalvar leaks or valvar insufficiency not seen by angiography. The peak catheterization gradient was more closely approximated by the mean ICE gradient (median difference -7.4 % between measurements) than by the peak ICE gradient (median difference 58.3 %; p < 0.0001). ICE provides excellent and safe visualization following Melody TPV implantation but did not provide new clinical information impacting management in this series. Selective use of ICE in cases with more than expected valve insufficiency or larger than expected residual gradients may streamline use while maintaining optimal clinical outcomes.
Collapse
|
32
|
Phillips ABM, Nevin P, Shah A, Olshove V, Garg R, Zahn EM. Development of a novel hybrid strategy for transcatheter pulmonary valve placement in patients following transannular patch repair of tetralogy of fallot. Catheter Cardiovasc Interv 2015; 87:403-10. [DOI: 10.1002/ccd.26315] [Citation(s) in RCA: 56] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/06/2015] [Revised: 08/11/2015] [Accepted: 10/09/2015] [Indexed: 11/08/2022]
Affiliation(s)
- Alistair B. M. Phillips
- The Guerin Family Congenital Heart Program, Cedars Sinai Medical Center; Los Angeles California
| | - Phillip Nevin
- The Guerin Family Congenital Heart Program, Cedars Sinai Medical Center; Los Angeles California
| | - Avni Shah
- The Guerin Family Congenital Heart Program, Cedars Sinai Medical Center; Los Angeles California
| | - Vincent Olshove
- The Guerin Family Congenital Heart Program, Cedars Sinai Medical Center; Los Angeles California
| | - Ruchira Garg
- The Guerin Family Congenital Heart Program, Cedars Sinai Medical Center; Los Angeles California
| | - Evan M. Zahn
- The Guerin Family Congenital Heart Program, Cedars Sinai Medical Center; Los Angeles California
| |
Collapse
|
33
|
Porras D, Gurvitz M, Marshall AC, Emani SM. Hybrid Approach for Off-Pump Pulmonary Valve Replacement in Patients With a Dilated Right Ventricular Outflow Tract. Ann Thorac Surg 2015; 100:e99-101. [DOI: 10.1016/j.athoracsur.2015.02.124] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/13/2014] [Revised: 01/21/2015] [Accepted: 02/02/2015] [Indexed: 12/31/2022]
|
34
|
Holzer RJ, Hijazi ZM. Transcatheter pulmonary valve replacement: State of the art. Catheter Cardiovasc Interv 2015; 87:117-28. [DOI: 10.1002/ccd.26263] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/06/2015] [Accepted: 09/16/2015] [Indexed: 01/09/2023]
Affiliation(s)
- Ralf J. Holzer
- Cardiac Catheterization and Interventional Therapy; Division Chief Cardiology (Acting); Sidra Cardiovascular Center of Excellence, Sidra Medical and Research Center; Doha Qatar
| | - Ziyad M. Hijazi
- Weill Cornell Medical College; Chief Medical Officer (Acting); Chair; Department of Pediatrics; Director; Sidra Cardiovascular Center of Excellence, Sidra Medical and Research Center; Doha Qatar
| |
Collapse
|
35
|
Suradi HS, Hijazi ZM. Percutaneous pulmonary valve implantation. Glob Cardiol Sci Pract 2015; 2015:23. [PMID: 26535223 PMCID: PMC4615899 DOI: 10.5339/gcsp.2015.23] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2015] [Accepted: 04/30/2015] [Indexed: 01/11/2023] Open
Affiliation(s)
- Hussam S Suradi
- Rush Center for Congenital & Structural Heart Disease, Rush University Medical Center, Chicago, IL, USA ; St Mary Medical Center, Community HealthCare Network, Hobart, IN, USA
| | - Ziyad M Hijazi
- Rush Center for Congenital & Structural Heart Disease, Rush University Medical Center, Chicago, IL, USA ; Sidra Cardiovascular Center of Excellence, Sidra Medical & Research Center, Doha, Qatar
| |
Collapse
|
36
|
Suleiman T, Kavinsky CJ, Skerritt C, Kenny D, Ilbawi MN, Caputo M. Recent Development in Pulmonary Valve Replacement after Tetralogy of Fallot Repair: The Emergence of Hybrid Approaches. Front Surg 2015; 2:22. [PMID: 26082929 PMCID: PMC4451578 DOI: 10.3389/fsurg.2015.00022] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2015] [Accepted: 05/18/2015] [Indexed: 11/13/2022] Open
Abstract
An increasing number of patients with tetralogy of Fallot require repeat surgical intervention for pulmonary valve replacement secondary to pulmonary regurgitation. Catheter-based interventions have emerged as an attractive alternative to surgery in this patient population but it is limited by patient size or the anatomy of the right ventricular outflow tract. Hybrid approaches involving both cardiac interventionists and surgeons are being developed to overcome these limitations. The purpose of this review is to highlight the recent advances in the hybrid field of pulmonary valve replacement, summarizing the advantages and disadvantages of the “traditional” surgical and the new catheter-based techniques and discuss the direction future research should take to determine the optimal management for individual patients.
Collapse
Affiliation(s)
| | | | | | - Damien Kenny
- Rush University Medical Center , Chicago, IL , USA
| | | | - Massimo Caputo
- Rush University Medical Center , Chicago, IL , USA ; Bristol Royal Hospital for Children, University of Bristol , Bristol , UK ; Bristol Heart Institute, University of Bristol , Bristol , UK
| |
Collapse
|
37
|
Abstract
Patients with congenital heart disease and pulmonary valve disease need multiple procedures over their lifetimes to replace their pulmonary valves. Chronic pulmonary stenosis, regurgitation, or both have untoward effects on ventricular function and on the clinical status of these patients. To date, all right ventricle-pulmonary artery conduits have had relatively short lifespans. Percutaneous pulmonary valve implantation, although relatively new, will probably reduce the number of operative procedures that these patients will have to undergo over a lifetime. Refinement and further development of this procedure holds promise for the extension of this technology to other patient populations.
Collapse
|
38
|
Wagner R, Daehnert I, Lurz P. Percutaneous pulmonary and tricuspid valve implantations: An update. World J Cardiol 2015; 7:167-177. [PMID: 25914786 PMCID: PMC4404372 DOI: 10.4330/wjc.v7.i4.167] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/28/2014] [Revised: 01/08/2015] [Accepted: 02/12/2015] [Indexed: 02/06/2023] Open
Abstract
The field of percutaneous valvular interventions is one of the most exciting and rapidly developing within interventional cardiology. Percutaneous procedures focusing on aortic and mitral valve replacement or interventional treatment as well as techniques of percutaneous pulmonary valve implantation have already reached worldwide clinical acceptance and routine interventional procedure status. Although techniques of percutaneous pulmonary valve implantation have been described just a decade ago, two stent-mounted complementary devices were successfully introduced and more than 3000 of these procedures have been performed worldwide. In contrast, percutaneous treatment of tricuspid valve dysfunction is still evolving on a much earlier level and has so far not reached routine interventional procedure status. Taking into account that an “interdisciplinary challenging”, heterogeneous population of patients previously treated by corrective, semi-corrective or palliative surgical procedures is growing inexorably, there is a rapidly increasing need of treatment options besides redo-surgery. Therefore, the review intends to reflect on clinical expansion of percutaneous pulmonary and tricuspid valve procedures, to update on current devices, to discuss indications and patient selection criteria, to report on clinical results and finally to consider future directions.
Collapse
|
39
|
Finch W, Levi DS, Salem M, Hageman A, Aboulhosn J. Transcatheter melody valve placement in large diameter bioprostheses and conduits: What is the optimal “Landing zone”? Catheter Cardiovasc Interv 2015; 86:E217-23. [DOI: 10.1002/ccd.25922] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/11/2014] [Accepted: 03/08/2015] [Indexed: 11/09/2022]
Affiliation(s)
- Will Finch
- Division of Cardiology; Department of Medicine, David Geffen School of Medicine at UCLA; Ahmanson/UCLA Adult Congenital Heart Disease Center; Los Angeles California
| | - Daniel S. Levi
- Division of Cardiology; Department of Medicine, David Geffen School of Medicine at UCLA; Ahmanson/UCLA Adult Congenital Heart Disease Center; Los Angeles California
- Division of Cardiology, Department of Pediatrics, David Geffen School of Medicine at UCLA; Los Angeles California
| | - Morris Salem
- Division of Cardiology, Department of Pediatrics; Kaiser Permanente Los Angeles Medical Center; Los Angeles California
| | - Abbie Hageman
- Division of Cardiology; Department of Medicine, David Geffen School of Medicine at UCLA; Ahmanson/UCLA Adult Congenital Heart Disease Center; Los Angeles California
| | - Jamil Aboulhosn
- Division of Cardiology; Department of Medicine, David Geffen School of Medicine at UCLA; Ahmanson/UCLA Adult Congenital Heart Disease Center; Los Angeles California
- Division of Cardiology, Department of Pediatrics, David Geffen School of Medicine at UCLA; Los Angeles California
| |
Collapse
|
40
|
Awad SM, Masood SA, Gonzalez I, Cao QL, Abdulla RI, Heitschmidt MG, Hijazi ZM. The use of intracardiac echocardiography during percutaneous pulmonary valve replacement. Pediatr Cardiol 2015; 36:76-83. [PMID: 25070389 DOI: 10.1007/s00246-014-0967-6] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/02/2014] [Accepted: 07/11/2014] [Indexed: 11/30/2022]
Abstract
High-quality live imaging assessment of cardiac valves and cardiac anatomy is crucial for the success of catheter-based procedures. We present our experience using Intracardiac echocardiography (ICE) during transcatheter Percutaneous Pulmonary Valve replacement (tPVR).This is a retrospective study that included 35 patients who underwent tPVR between April 2008 and June 2012. Thirty-one of these patients had the procedure performed under continuous ICE guidance. Pre-procedure transthoracic echocardiography (TTE) was obtained in all patients. ICE was performed at baseline, during the procedure, and at the conclusion of the procedure. Comparisons between the pre-procedure TTE and baseline ICE data and between post-procedure ICE data and the following day TTE were performed. Total of 35 patients had tPVR during the above-mentioned time period. Twenty-one patients received the Edwards Sapien valve and 14 patients had the Melody valve. Thirty-one patients had the procedure performed under continuous ICE guidance. The mean Pre-TTE peak gradient (PG) and Pre-ICE-PG were 45.5 ± 20 vs 33 ± 13 mmHg (p < 0.001) and the mean Pre-TTE mean gradient (MG) and Pre-ICE-MG were 27.7 ± 13 vs 21 ± 18 mmHg (p < 0.001). The mean Post-TTE- PG and Post-ICE-PG were 24.3 ± 11 vs 15.3 ± 7 mmHg (p < 0.001) and the mean of the Post-TTE-MG and Post-ICE-MG were 14.2 ± 7 vs 8.4 ± 4 mmHg (p < 0.001). There was a good correlation between peak ICE and TTE gradient at baseline and after valve placement. For the degree of pulmonary regurgitation, there was no significant difference between TTE and ICE. ICE is an important modality to guide tPVR in patients with dysfunctional homograft valve between the right ventricle and pulmonary artery and should be used to assess valve function before, during and immediately after the procedure.
Collapse
Affiliation(s)
- Sawsan M Awad
- Rush Centre for Congenital and Structural Heart Disease, Rush University Medical Centre, Chicago, IL, 60612, USA,
| | | | | | | | | | | | | |
Collapse
|
41
|
Leventhal A, Shah A, Osten M, Benson L, Horlick E. Transcatheter valve-in-valve therapy: What does the pediatric cardiologist need to know? PROGRESS IN PEDIATRIC CARDIOLOGY 2014. [DOI: 10.1016/j.ppedcard.2014.12.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
42
|
Transcatheter pulmonary valve insertion, expanded use (beyond large conduits from the right ventricle to pulmonary artery), and future directions. Cardiol Young 2014; 24:1095-100. [PMID: 25647384 DOI: 10.1017/s1047951114002005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Transcatheter pulmonary valve insertion is the most important advance in congenital interventional cardiology since atrial septal defect devices became commonly available 15 years ago. It has changed the way we look at a number of diverse diagnoses and changes how we plan, diagnose, operate, and follow-up patients. It has changed how we counsel families expecting a child that may benefit from it. Expanded use of the Melody® valve, outside its United States Food and Drug Administration approved indications, has helped numerous additional patients. The use of transcatheter pulmonary valve insertion in selected patients following surgical Gore-tex® bileaflet in valve right ventricular outflow tract reconstruction and those with a history of prior small homograft conduits will be discussed.
Collapse
|
43
|
The future of transcatheter pulmonary valvulation. Arch Cardiovasc Dis 2014; 107:635-42. [PMID: 25241221 DOI: 10.1016/j.acvd.2014.07.046] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/12/2014] [Revised: 06/30/2014] [Accepted: 07/01/2014] [Indexed: 10/24/2022]
Abstract
Percutaneous pulmonary valve implantation now has a key role in the setting of dysfunctional right ventricle-to-pulmonary artery conduits or failing bioprosthetic pulmonary valves. However, despite the excellent results obtained with the two devices available currently (the Melody(®) valve [Medtronic Inc., Minneapolis, MN, USA] and the Edwards SAPIEN(®) valve [Edwards Lifesciences, Irvine, CA, USA]), many patients eligible for pulmonary valve replacement remain unsuitable for percutaneous pulmonary valve implantation, mainly because of large native outflow tracts. Accordingly, one of the major challenges for the future is to expand percutaneous pulmonary valve implantation to a broader population of patients. Moving forward, there is important ongoing research that is intended to improve patient outcomes, expand percutaneous pulmonary valve implantation therapy and continue to reduce the number of open-heart surgeries in this population. In this review, we underline the limitations and issues associated with the devices available currently, and we focus on the development of new strategies (such as hybrid approaches or magnetic resonance-guided procedures), new devices (such as right ventricular outflow tract reducers or the novel Native Outflow Tract valved stent from Medtronic) and new technologies (such as tissue-engineered valves), which may help to take up these challenges and represent the future of transcatheter valve implantation.
Collapse
|
44
|
Martin MH, Gruber PJ, Gray RG. Transcatheter neoaortic valve replacement utilizing the melody valve in hypoplastic left heart syndrome. Catheter Cardiovasc Interv 2014; 85:615-9. [DOI: 10.1002/ccd.25472] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/17/2013] [Revised: 12/30/2013] [Accepted: 03/02/2014] [Indexed: 11/08/2022]
Affiliation(s)
- Mary Hunt Martin
- Department of Pediatric Cardiology; University of Utah at Primary Children's Medical Center; Salt Lake City Utah
| | - Peter J. Gruber
- Department of Pediatric Cardiothoracic Surgery; University of Utah at Primary Children's Medical Center; Salt Lake City Utah
| | - Robert G. Gray
- Department of Pediatric Cardiology; University of Utah at Primary Children's Medical Center; Salt Lake City Utah
| |
Collapse
|
45
|
Abstract
PURPOSE OF REVIEW Catheter-based valve technologies have evolved rapidly over the last decade. Transcatheter aortic valve replacement (TAVR) has become a routine procedure in high-risk adult patients with calcific aortic stenosis. In patients with congenital heart disease (CHD), transcatheter pulmonary valve replacement represents a transformative technology for right ventricular outflow tract dysfunction with the potential to expand to other indications. This review aims to summarize the current state-of-the-art for transcatheter valve replacement (TVR) in CHD; the expanding indications for TVR; and the technological obstacles to optimizing TVR. RECENT FINDINGS Multiple case series have demonstrated that TVR with the Melody transcatheter pulmonary valve in properly selected patients is safe, effective, and durable in short-term follow-up. The Sapien transcatheter heart valve represents an alternative device with similar safety and efficacy in limited studies. Innovative use of current valves has demonstrated the flexibility of TVR, while highlighting the need for devices to address the broad range of postoperative anatomies either with a single device or with strategies to prepare the outflow tract for subsequent device deployment. SUMMARY The potential of TVR has not been fully realized, but holds promise in treatment of CHD.
Collapse
|
46
|
Meadows JJ, Moore PM, Berman DP, Cheatham JP, Cheatham SL, Porras D, Gillespie MJ, Rome JJ, Zahn EM, McElhinney DB. Use and Performance of the Melody Transcatheter Pulmonary Valve in Native and Postsurgical, Nonconduit Right Ventricular Outflow Tracts. Circ Cardiovasc Interv 2014; 7:374-80. [DOI: 10.1161/circinterventions.114.001225] [Citation(s) in RCA: 92] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Affiliation(s)
- Jeffery J. Meadows
- From the Division of Cardiology, UCSF Benioff Children’s Hospital, University of California, San Francisco (J.J.M., P.M.M.); Division of Cardiology, Miami Children’s Hospital, FL (D.P.B.); Division of Cardiology, Nationwide Children’s Hospital, Ohio State University School of Medicine, Columbus (J.P.C., S.L.C.); Department of Cardiology, Children’s Hospital Boston, MA (D.P.); Division of Cardiology, The Children’s Hospital of Philadelphia, PA (M.J.G., J.J.R.); Division of Cardiology, Cedars-Sinai
| | - Phillip M. Moore
- From the Division of Cardiology, UCSF Benioff Children’s Hospital, University of California, San Francisco (J.J.M., P.M.M.); Division of Cardiology, Miami Children’s Hospital, FL (D.P.B.); Division of Cardiology, Nationwide Children’s Hospital, Ohio State University School of Medicine, Columbus (J.P.C., S.L.C.); Department of Cardiology, Children’s Hospital Boston, MA (D.P.); Division of Cardiology, The Children’s Hospital of Philadelphia, PA (M.J.G., J.J.R.); Division of Cardiology, Cedars-Sinai
| | - Darren P. Berman
- From the Division of Cardiology, UCSF Benioff Children’s Hospital, University of California, San Francisco (J.J.M., P.M.M.); Division of Cardiology, Miami Children’s Hospital, FL (D.P.B.); Division of Cardiology, Nationwide Children’s Hospital, Ohio State University School of Medicine, Columbus (J.P.C., S.L.C.); Department of Cardiology, Children’s Hospital Boston, MA (D.P.); Division of Cardiology, The Children’s Hospital of Philadelphia, PA (M.J.G., J.J.R.); Division of Cardiology, Cedars-Sinai
| | - John P. Cheatham
- From the Division of Cardiology, UCSF Benioff Children’s Hospital, University of California, San Francisco (J.J.M., P.M.M.); Division of Cardiology, Miami Children’s Hospital, FL (D.P.B.); Division of Cardiology, Nationwide Children’s Hospital, Ohio State University School of Medicine, Columbus (J.P.C., S.L.C.); Department of Cardiology, Children’s Hospital Boston, MA (D.P.); Division of Cardiology, The Children’s Hospital of Philadelphia, PA (M.J.G., J.J.R.); Division of Cardiology, Cedars-Sinai
| | - Sharon L. Cheatham
- From the Division of Cardiology, UCSF Benioff Children’s Hospital, University of California, San Francisco (J.J.M., P.M.M.); Division of Cardiology, Miami Children’s Hospital, FL (D.P.B.); Division of Cardiology, Nationwide Children’s Hospital, Ohio State University School of Medicine, Columbus (J.P.C., S.L.C.); Department of Cardiology, Children’s Hospital Boston, MA (D.P.); Division of Cardiology, The Children’s Hospital of Philadelphia, PA (M.J.G., J.J.R.); Division of Cardiology, Cedars-Sinai
| | - Diego Porras
- From the Division of Cardiology, UCSF Benioff Children’s Hospital, University of California, San Francisco (J.J.M., P.M.M.); Division of Cardiology, Miami Children’s Hospital, FL (D.P.B.); Division of Cardiology, Nationwide Children’s Hospital, Ohio State University School of Medicine, Columbus (J.P.C., S.L.C.); Department of Cardiology, Children’s Hospital Boston, MA (D.P.); Division of Cardiology, The Children’s Hospital of Philadelphia, PA (M.J.G., J.J.R.); Division of Cardiology, Cedars-Sinai
| | - Matthew J. Gillespie
- From the Division of Cardiology, UCSF Benioff Children’s Hospital, University of California, San Francisco (J.J.M., P.M.M.); Division of Cardiology, Miami Children’s Hospital, FL (D.P.B.); Division of Cardiology, Nationwide Children’s Hospital, Ohio State University School of Medicine, Columbus (J.P.C., S.L.C.); Department of Cardiology, Children’s Hospital Boston, MA (D.P.); Division of Cardiology, The Children’s Hospital of Philadelphia, PA (M.J.G., J.J.R.); Division of Cardiology, Cedars-Sinai
| | - Jonathan J. Rome
- From the Division of Cardiology, UCSF Benioff Children’s Hospital, University of California, San Francisco (J.J.M., P.M.M.); Division of Cardiology, Miami Children’s Hospital, FL (D.P.B.); Division of Cardiology, Nationwide Children’s Hospital, Ohio State University School of Medicine, Columbus (J.P.C., S.L.C.); Department of Cardiology, Children’s Hospital Boston, MA (D.P.); Division of Cardiology, The Children’s Hospital of Philadelphia, PA (M.J.G., J.J.R.); Division of Cardiology, Cedars-Sinai
| | - Evan M. Zahn
- From the Division of Cardiology, UCSF Benioff Children’s Hospital, University of California, San Francisco (J.J.M., P.M.M.); Division of Cardiology, Miami Children’s Hospital, FL (D.P.B.); Division of Cardiology, Nationwide Children’s Hospital, Ohio State University School of Medicine, Columbus (J.P.C., S.L.C.); Department of Cardiology, Children’s Hospital Boston, MA (D.P.); Division of Cardiology, The Children’s Hospital of Philadelphia, PA (M.J.G., J.J.R.); Division of Cardiology, Cedars-Sinai
| | - Doff B. McElhinney
- From the Division of Cardiology, UCSF Benioff Children’s Hospital, University of California, San Francisco (J.J.M., P.M.M.); Division of Cardiology, Miami Children’s Hospital, FL (D.P.B.); Division of Cardiology, Nationwide Children’s Hospital, Ohio State University School of Medicine, Columbus (J.P.C., S.L.C.); Department of Cardiology, Children’s Hospital Boston, MA (D.P.); Division of Cardiology, The Children’s Hospital of Philadelphia, PA (M.J.G., J.J.R.); Division of Cardiology, Cedars-Sinai
| |
Collapse
|
47
|
Travelli FC, Herrington CS, Ing FF. A novel hybrid technique for transcatheter pulmonary valve implantation within a dilated native right ventricular outflow tract. J Thorac Cardiovasc Surg 2014; 148:e145-6. [PMID: 24929802 DOI: 10.1016/j.jtcvs.2014.04.046] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/07/2014] [Revised: 04/17/2014] [Accepted: 04/24/2014] [Indexed: 11/19/2022]
Affiliation(s)
- Frances C Travelli
- Division of Cardiology, Department of Pediatrics, Children's Hospital Los Angeles, University of Southern California, Los Angeles, Calif
| | - Cynthia S Herrington
- Division of Cardiology, Department of Cardiothoracic Surgery, Children's Hospital Los Angeles, University of Southern California, Los Angeles, Calif
| | - Frank F Ing
- Division of Cardiology, Department of Pediatrics, Children's Hospital Los Angeles, University of Southern California, Los Angeles, Calif.
| |
Collapse
|
48
|
Hasan BS, Lunze FI, Chen MH, Brown DW, Boudreau MJ, Rhodes J, McElhinney DB. Effects of Transcatheter Pulmonary Valve Replacement on the Hemodynamic and Ventricular Response to Exercise in Patients With Obstructed Right Ventricle-to-Pulmonary Artery Conduits. JACC Cardiovasc Interv 2014; 7:530-42. [DOI: 10.1016/j.jcin.2014.02.006] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2013] [Revised: 01/20/2014] [Accepted: 02/13/2014] [Indexed: 01/28/2023]
|